cyrilzakka/clinical-trials huggingface dataset:
Timolol Eye Drops in the Treatment of Acute Migraine Headache

The goal of this study is to determine whether timolol eye drops are effective in alleviating acute migraine headaches. Subjects will be randomized to receive either timolol eye drops or placebo (tears) to use as a migraine abortive medication.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of migraine headache

Exclusion Criteria

* Non-migraine headache
* Use of systemic beta-blocker
* Medical history of hypotension, bradycardia, syncope or other significant cardiovascular disease
* Medical history of difficulty breathing, asthma or chronic obstructive pulmonary disease or other pulmonary disease
* Medical history of glaucoma, ocular hypertension or hypotony, punctual stenosis, current use of other ophthalmic medications
* Previous adverse reaction to timolol or other beta-blockers
* Inability to self-administer eye drop due to physical or cognitive disorders
* Currently pregnant or breastfeeding
* Pregnant in the past year
* Non-english speaker
Effect of Chewing Gum and Mouthwash Before Operation on Sore Throat After General Anesthesia With a Laryngeal Mask

Postoperative sore throat (POST) is an important problem after general anaesthesia. We assessed whether chewing gum preoperatively or mouthwash can reduce the incidence of POST after general anaesthesia administered via a streamlined liner of the pharyngeal airway (SLIPA).


Eligibility Criteria:
Inclusion Criteria:

American Society of Anaesthesiologists(ASA)class I or II 20\~65 years body mass index(BMI)scores\<30 undergoing elective hysteroscopic surgery

Exclusion Criteria:

chronic laryngitis chronic bronchitis asthma gastroesophageal reflux allergies to study drugs recent use of non-steroidal anti-inflammatory drugs(NSAIDS) a history of upper respiratory tract infection in the past one week Mallampati grade\>2 a history of steroid therapy.
Efficacy and Safety Oral Contraceptive Study

The purpose of this study is to determine whether the study drug is effective in prevention of pregnancy in healthy women in reproductive age

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Eligibility Criteria:
Inclusion Criteria:

* Healthy woman requesting contraception
* Age between 18 and 35 years (inclusive), smokers maximum age of 30 years (inclusive)

Exclusion Criteria:

* Any conditions might interfere study outcome
Evaluation of Bladder Volumes in Patients Receiving Radiotherapy to the Rectum, Using Kilovoltage Cone-beam Imaging

The purpose of this study is to implement and access a newly developed bladder filling protocol for patients receiving radiotherapy for rectal cancer using imaging on the treatment unit.


Eligibility Criteria:
Inclusion Criteria:

* Patients receiving radical radiotherapy to rectal malignancies.
* Age \> 18 years old
* No previous lower GI radiotherapy
* Written informed consent according to good clinical practice (GCP) and national / local regulations.

Exclusion Criteria:

* Patients receiving palliative radiotherapy to rectal malignancies.
* Patients receiving radical short course preoperative radiotherapy for rectal malignancies.
* Patients unable to give informed consent.
An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.

The initial intent was to enroll 12-24 adult male and female participants on hemodialysis into the study. Due to significant recruitment challenges, the study was discontinued after six participants were enrolled in the study.

This was an open-label, multiple-dose, adaptive-design study in participants on hemodialysis. Eligible participants on hemodialysis were to remain in the Clinical Research Unit for 2 weeks (Day -7 to Day 8) and were required to consume a potassium, magnesium, calcium and sodium-controlled diet.

Eligibility Criteria:
Inclusion Criteria:

* Participants on hemodialysis between the ages of 18 and 70 years, with serum potassium levels of at least 5.5 mmol/L
* Adequately dialyzed (Kt/V ≥ 1.2)

Exclusion Criteria:

* History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders or major gastrointestinal surgery.
* Severe constipation or irregular bowel habits.
* Unable to consume or tolerate the study-specific diet.
Adaptation of Insulin Delivery Settings to Improve Clinical Outcomes With AID Use

Obtain preliminary safety and performance data on a settings initialization and adaptation algorithm used in conjunction with closed-loop control.

This feasibility study is a prospective, single arm, single center study with a run-in phase, followed by 13 weeks of Control-IQ technology use. By using an algorithm to more accurately initialize insulin delivery settings and adapt them over time, faster than typical HCP visits, users onboarding from multiple daily injections (MDI) will reach optimal glycemic outcomes faster.

Eligibility Criteria:
Inclusion Criteria:

* Adult subjects ≥ age 18 years
* Clinical diagnosis of type 1 diabetes for at least one year
* Using a basal/bolus regimen by injection (MDI therapy)
* Total daily dose ≥10 units/day
* Willing to use only aspart (novolog) or lispro (humalog) U-100 insulin with the study pump.
* A1c ≥ 7.5% and ≤ 11% at screening
* Not pregnant or planning a pregnancy during the time period of the study.
* Has current glucagon product to treat severe hypoglycemia (injectable or nasal) at home (will provide prescription if they do not have one)
* Willingness to follow study procedures and a signed informed consent form

Exclusion Criteria:

* Two or more episodes of severe hypoglycemia (needing assistance) in the past 6 months
* Two or more episodes of diabetic ketoacidosis in the past 6 months
* Inpatient psychiatric treatment in the past 6 months
* History of drug abuse (defined as any illicit drug use) or history of alcohol abuse prior to screening or unwillingness to agree to abstain from illicit drugs throughout the study
* Significant chronic kidney disease or hemodialysis
* Significant liver disease
* History of adrenal insufficiency
* Hypothyroidism or hyperthyroidism that is not appropriately treated
* Other chronic disease/condition determined by investigator to interfere with participation in the study
* Use of glucocorticoids, beta blockers or other medications determined by investigator to interfere with study
* Use of long-acting insulin, inhaled insulin (Afrezza), or use of any non-insulin glucose lowering agents (i.e. SGLT-2 inhibitor) other than Metformin with the study pump
* Subject is pregnant or lactating or intending to become pregnant before or during participation in this study
* Investigator judgement that subject would not be able to complete the trial
Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation

Stroke and abdominal aortic aneurysms (AAAs) are common and highly lethal vascular diseases. Angiogenesis and infiltration of inflammatory cells such as macrophages may cause stroke and AAAs.

The purpose of this study is to test PET/CT and PET/MRI imaging to specifically detect those diseases using a new developed agent (18F-FPPRGD2) that can target angiogenesis and macrophages.

20 subjects with either carotid bifurcation stenosis of \>50% by ultrasound on at least one side (10 patients) or advanced AAAs (10 patients) and surgical intervention planned will be identified from physicians from the Division of Vascular Surgery at Stanford.

Either a PET/CT or a PET/MRI will be performed for each subject:

* PET/CT scans will be performed in 3D mode using GE Discovery 600 or GE Discovery 690 scanners (GE Healthcare).
* PET/MRI scans will be performed using the novel PET/MRI system at Stanford, including a sensitive PET time-of-flight (TOF) scanner with an advanced 3T MRI scanner.

The study patients will receive an intravenous administration of 10mCi of the prescribed radiotracer (18F-FPPRGD2). PET/CT or PET/MRI images will be obtained starting 45-60 minutes after radiotracer administration. For PET/CT, each image acquisition will begin with a non-contrast CT scan obtained from the vertex through the mid-thighs of the subjects. For PET/MRI, non-contrast images of the carotid or aorta will be performed. PET imaging will follow. Patient's vital signs will be monitored during the procedure and a physician will be available if there is need for immediate medical attention. The PET images will be reconstructed with a standard iterative algorithm using GE software release 5.0.

After the planned surgery, we will also assess the histopathological correlation between the disease lesions and PET/CT or PET/MRI imaging characteristics.

Eligibility Criteria:
Inclusion Criteria:

* Greater than 18 year-old at the time of radiotracer administration
* Provides written informed consent
* Patients diagnosed with either carotid artery stenosis or abdominal aortic aneurysms (AAAs) as identified in Vascular Surgery, in whom a surgical procedure is scheduled
* Able to remain still for duration of an imaging procedure (about one hour).

Exclusion Criteria:

* Less than 18 year-old at the time of radiotracer administration
* Unable to provide written informed consent
* Pregnant women
* Prior carotid or abdominal surgery
* History of radiation therapy to the neck and abdomen
* MRI contraindications (including ferromagnetic objects or devices).
Propofol TCI Administered by Gastroenterologists During Endoscopy: a Randomized Double Blind Controlled Study

Many studies address safety and effectiveness of non-anesthesiologist propofol sedation (NAPS) for GI endoscopy. Target Controlled Infusion (TCI) is a sophisticated tool for providing optimal sedation regimen and avoiding under or oversedation.

This randomized double blind controlled study compares standard moderate sedation level of sedation (group S) during upper endoscopy (EGD) and colonoscopy (CS) versus propofol NAPS (group P).

70 CS and 70 EGD ASA I-II patients were studied. In group S (n=70) we administered fentanyl (1μg/kg) + midazolam (0.04-0.03 mg/kg) for CS and midazolam (0.04-0.03 mg/kg) for EGDS and in group P (n=70) fentanyl 1µg/Kg + propofol TCI 1.2-1.6 μg/ml for CS and propofol TCI 1.2-1.6 μg/ml for EGD. Vital parameters and Observer's Assessment of Alertness and Sedation Scale (OAA/S) were monitored throughout the study. Endoscopist's and patient's satisfactions were measured after procedure and 24-72 h later by visual analog scale (VAS).

Eligibility Criteria:
Inclusion Criteria:

* age \>18 yrs
* ASA (American Society of Anesthesiologists risk class III-IV)I-II
* patients undergoing to gastroscopy or colonoscopy

Exclusion Criteria:

* significant systemic disease (American Society of Anesthesiologists risk class III-IV)
* history of allergic reactions to any of the study drugs
* chronic use of opioid analgesics
* psychiatric disorder
* pregnancy
* difficult airways (Mallampati score \>2)
* age \<18 yrs
Multicenter Clinical Trial of Buprenorphine - 3

The purpose of this study is to test the efficacy and safety of buprenorphine.

12 different sites for a total of 736 subjects (60 at Pizarro, 70 at West LA Tx center, 15 in the 1 year extension)

Eligibility Criteria:
Inclusion Criteria:

M/F, ages 21-50. opiate dependence according to DSM-IV criteria. Self-reported use within the last 30 days. Agreeable to conditions of the study and signed informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hynotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.
Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms

Automated immunodosage methods (Roche Elecsys cortisol and IDS cortisol dosing kits) offer a simple and inexpensive technology routinely used in a medical biology laboratory. They can be used to define robust diagnostic thresholds for salivary cortisol for the diagnosis of Cushing's syndrome and pseudo-Cushing combining the three tests performed as part of the patient's usual management. (ie two urinary free cortisol (UFC), the dexamethasone suppression test, and Diurnal variation of plasma cortisol).


Eligibility Criteria:
Inclusion Criteria:

* The patient is under consultation in the department of metabolic and endocrine disorders at the CHU Nimes for diagnosis or follow-up of hypercortisol assessment
* The patient must be a member or beneficiary of a health insurance plan

Exclusion Criteria:

* The patient is pregnant, parturient or breastfeeding
* The patient has a cardiovascular or metabolic state against the indication of dexamethasone

  - Patient with DFG \< 30 ml/min/1.73 m2
* The patient has suffered urinary incontinence rendering 24-hour urinary collection impossible or non-interpretable
* The patient has a urinary catheter
* The patient is taking corticoids (oral, inhaled, intra-venous or cutaneous)

  .Patient exposed to interfering treatments (Itraconazole, ritonavir, megestrol acetate, medroxyprogesterone acetate, TSH, estrogen-progestogen pill, hormonal coil)
* The subject is in a period of exclusion determined by a previous study
* The subject opposes their participation in the study
* It is impossible to give the subject informed information
* The patient is under safeguard of justice or state guardianship
Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance

The hypothesis is that GHRP-3 will exert beneficial effects on endothelial function and insulin resistance in older men and women via hormonal (GH, IGF-I, IGFBP-3,-1, insulin) and non-hormonal actions (anti-inflammatory).

At the lower dose of 0.1 µg/kg/h, GHRP-3 presumably will improve endothelial dysfunction, enhance insulin action and lower blood pressure via the anti-inflammatory effects of GHRP-3 while at the higher dose of 0.5 µg/kg/h GHRP-3 these anti-inflammatory effects will be further augmented by the hormonal action of increasing serum IGF-I and its primary serum binding protein insulin like growth hormone binding protein - 3 (IGFBP-3 as well as -1). Also, the more detailed inter-relationships between the actions of GHRP-3, GH and IGF-I on serum glucose, blood pressure, and lipid levels over 24h periods will be determined at the end of the 14 day placebo and two GHRP-3 infusion periods. The GHRP-3 will be administered in escalating doses.

The Specific Aims of this study are as follows:

1. To determine the relative effects of 0.1µg/kg/h and 0.5µg/kg/h GHRP-3 as compared to placebo infusion in inducing physiological secretion of the GH-IGF-I system after continuous sc delivery for 14 days in healthy older men and women with insulin resistance.
2. To determine the relative interrelated effects of 0.1 and 0.5µg/kg/h GHRP-3 infusion and placebo on various hormonal and non hormonal aspects of insulin resistance such as blood pressure (BP), plasma glucose and FFA as well as GH, IGF-I, IGFBP-1, -3, insulin and endothelin-1 levels.
3. To determine the relative effects of placebo and the above 2 doses of GHRP-3 infusion on flow mediated dilation (FMD) and nitroglycerin-dependent dilation

Eligibility Criteria:
Inclusion Criteria:

1. Men and post-menopausal women 50-70 years.
2. Elevated fasting plasma glucose ranging \<125 mg/dL
3. Waist circumference \>35 inches in women and \>40 inches in men

Exclusion Criteria:

1. Patients taking medications that may alter carbohydrate metabolism and/or insulin resistance.
2. Female patients with a positive pregnancy test.
3. Previous history of hypersensitivity to GHRP.
4. Patients with overt liver disease, renal disease and/or congestive heart failure.
5. Patients with anticipated change in medication regimen during the study period.
6. Current use or history of use of hormone replacement therapy in the last six months.
7. Current use or history of use of Ace Inhibitors or Angiotensin receptor blockers in the last six months.
8. Hemoglobin of \< 11.6 g/dL for women and \< 12.9 g/dL for men.
Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

The purpose of this study is to determine the safety and efficacy of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor) Conditioning Regimen in Patients with Relapsed/refractory Acute Leukemia undergoing allogeneic peripheral blood stem cell transplantation.

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the only way to cure relapsed/refractory acute leukemia. Busulfan/Cyclophosphamide (BuCy, Cytarabine, Busulfan, Cyclophosphamide) has been a classical conditioning regimen for allo-SCT. Substitution of Cyclophosphamide in the BuCy regimen with Fludarabine (BuF) resulted in reduced toxicity and similar efficacy. FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor) is a chemotherapy regimen that has been proved to be effective for relapsed/refractory acute leukemia as salvage therapy. To reduce the relapse and improve the survival of those patients with relapsed/refractory acute leukemia who receive allo-SCT, the novel conditioning regimen consisting of Busulfan/FLAG was developed. The combination of Bu and FLAG without interval shortens the duration of conditioning and the pneutropenic period of the patient compared with successive administration of FLAG followed with BuF. In addition, regarding the established safety and efficacy of BuF and FLAG, it is reasonable to expect similar safety and enhanced antileukemic efficacy for Bu/FLAG compared with BuF. In this study, the safety and efficacy of this regimen in patients with relapsed/refractory acute leukemia undergoing allogeneic peripheral blood stem cell transplantation was investigated.

Eligibility Criteria:
Inclusion Criteria:

* relapsed/refractory acute leukemia regardless of cytogenetics
* All patients should aged 12 to 65 years
* Have matched sibling donors, ≥8/10 HLA(human leukocyte antigen) matched unrelated donors or haploidentical donors
* Patients without any uncontrolled infections or without severe pulmonary, renal, hepatic or cardiac diseases

Exclusion Criteria:

* Patients aged less than 12 years old
* Patients with any uncontrolled infections or with severe pulmonary, renal, hepatic or cardiac diseases
* Acute myeloid leukemia patients with t (15;17)
Activity Therapy After Kidney Transplant

To combat post-transplant weight gain, we seek to expand Stanford Kidney Transplant's multidisciplinary platform to include physical activity monitoring and coaching using the Apple Watch.


Eligibility Criteria:
Inclusion Criteria:

* All adults (18 years) who undergo kidney transplant at Stanford.

Exclusion Criteria:

* Poor vision with inability to use Apple Watch
* Permanently unable to ambulate
Psychosocial Benefits of Gratitude Journals

This randomized controlled study will examine the effects of different interpersonal gratitude journals compared to a neutral control journal on psycho social outcomes.

This randomized controlled study will examine the effect of a) a reflective interpersonal gratitude journal, and b) an reflective and behavioral interpersonal gratitude journal, versus (c) an active control journal, on life satisfaction and other secondary outcomes. Explanatory mechanisms will be tested utilizing the broaden-and-build theory of positive emotions. Participants will be randomly assigned to one of these three conditions with three week, one month and three month follow-up assessments.

Eligibility Criteria:
Inclusion Criteria:

* English language proficiency

Exclusion Criteria:

* under the age of 18
Evaluation of CMV/EBV-CMI in Haploid HSCT

The purpose of this prospective, open-label, Single Arm, single-center study is to evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for patients with hemopathy undergoingin prophylaxis for cytomegalovirus in haploid hematopoietic stem cell transplantation(haplo-HSCT) .


Eligibility Criteria:
Inclusion Criteria:

1. All patients were diagnosed with hemopathy.
2. All patients should have the indication of Haploidentical hematopoietic stem cell transplant and receive the prophylaxis for cytomegalovirus.
3. All patients should sign an informed consent document indicating that they understand the purpose of and procedures required for the study and be willing to participate in the study.

Exclusion Criteria:

Patients with any conditions not suitable for the trial (investigators' decision).
Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

This is a long-term, double-blind, placebo-controlled study of MCI-186 to treat ALS. This study is the long-term extension of Study NCT00330681; Study NCT00330681 is a Phase 3, randomized, double-blind, placebo control, parallel assignment, 24-week study in the treatment of ALS. The objectives of this study are to assess the efficacy and safety of long-term intermittent therapy with 60 mg MCI-186 to ALS patients.


Eligibility Criteria:
Inclusion Criteria:

* Patients who ware completed drug administration without discontinuation in the preceding confirmatory study NCT00330681.

Exclusion Criteria:

* Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone.
* Patients whose creatinine clearance is 50mL/min or less at the time of completion of drug administration in the study NCT00330681.
* Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception.
* Patients who are participating in other clinical trials except the study NCT00330681.
* In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.